West Pharmaceutical Services, Inc. executives delivered a 30-minute presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, highlighting a 12% year-over-year increase in total revenue during the third quarter and record demand for isolator technology in prefilled syringe manufacturing. The company emphasized its five-year strategic plan to expand production capacity by 20% globally through the addition of two new high-speed assembly lines in Switzerland and Malaysia, expected to come online by late 2024. Leadership also noted a 15% improvement in operating margins driven by productivity gains and the pending launch of a next-generation polymer-based containment device for biologics.

An average of 15 Wall Street analysts has set price targets implying a potential 26.42% upside for West Pharmaceutical Services over the next 12 months. Analysts raised full-year adjusted earnings estimates by an average of 8% over the past quarter, citing stronger demand in the contract-manufacturing segment and improved raw-material sourcing. Five analysts upgraded their ratings during the past six weeks, with two moving from Hold to Buy following the company’s announced capital spending plan of $250 million for capacity expansion and automation upgrades through 2025.

AbbVie Inc. has entered into a definitive agreement to acquire West Pharmaceutical Services’ Tempe, Arizona device manufacturing facility and associated intellectual property for $175 million, with the transaction expected to close in mid-2026. The deal transfers three production lines capable of producing 3.5 mL on-body injector devices, which currently support WST’s contract-manufacturing customers. West will receive the cash proceeds upfront and retain responsibility for employee transitions as AbbVie plans to hire approximately 200 facility staff and invest an additional $50 million to modernize and integrate the site into its global network.